Skip to main content

Table 2 Comparison Between Baseline Clinicopathological Characteristics of COVID-19 VS control group

From: The impact of COVID-19 on the prognosis of deep vein thrombosis following anticoagulation treatment: a two-year single-center retrospective cohort study

Characteristics

Unmatched cohort(n = 197)

 

1:2 Propensity score matching (n = 177)

 

COVID-19

(n = 69)

Contral

(n = 128)

P value

 

COVID-19

(n = 65)

Contral

(n = 112)

P value

Demographics

       

 Gender (Male/Female)

40/29

82/46

0.401

 

39/26

71/41

0.654

 Age (Mean), years

66

66

0.619

 

66

66

0.491

 BMI (Mean)

22

23

0.353

 

23

24

0.08

 DBP(M ± SD), mmHg

74.71 ± 18.33

76.69 ± 11.52

0.135

 

78 ± 9.09

76.73 ± 12.06

0.356

DVT attributes

       

 Type of DVT

 (Unilateral distal/Unilateral proximal/Bilateral distal/Bilateral proximal )

28/15/18/8

51/36/30/11

0.739

 

26/15/18/6

42/32/28/10

0.884

 Risk stratification of DVT (None/Low/High)

4/33/32

3/77/48

0.166

 

1/33/31

1/63/48

0.743

 PE (None/Periphery/Central)

44/23/2

74/41/13

0.184

 

42/21/2

65/34/13

0.144

 Mean follow up (Range), days

148.16 (91–484)

176.02(91–487)

0.002

 

149(91–484)

174.9(56–487)

0.004

 Anticoagulant therapy (3 months/ Extended period)

45/24

78/50

0.554

 

42/23

69/43

0.69

 Therapeutic outcomes (Stable condition/Remission/Aggravation)

24/14/31

32/73/23

< 0.001

 

23/13/29

28/64/20

< 0.001

Clinical diagnosis

  

0.235

   

0.34

 Advanced lung cancer (SCC/adenocarcinoma/SCLC)

5/27/5

15/38/4

  

5/27/4

5/36/4

 

 Postoperative

8

16

 

8

16

 Benign lung diseases (None/Interstitial lung disease/Tuberculosis/ COPD/Pneumonia/Bronchiectasis/PAH)

4/2/3/7/2/3/3

5/7/10/6/15/9/3

 

2/2/3/7/2/2/3

5/6/9/6/14/8/3

Time from active ongoing treatment to DVT confirmed, months (< 6/6–12/>12)

54/5/10

112/10/6

0.056

 

48/7/10

96/10/6

0.066

Relevant blood biochemistry tests

       

 RBC (< 4.3*1012/L / >4.3*1012/L)

37/32

78/50

0.364

 

34/31

72/40

0.152

 WBC (< 9.5*1012/L / >9.5*1012/L)

58/11

95/33

0.153

 

52/13

79/33

0.214

 PLT (< 125*109/L / >125*109/L)

11/58

19/109

0.838

 

8/57

18/94

0.66

 D-dimer level (Decreased / Increased)

43/26

90/38

0.253

 

41/24

73/29

0.778

 PT (< 11s / >11s)

13/56

21/107

0.695

 

11/54

17/95

0.832

  1. BMI, body mass index; DBP, diastolic blood pressure; DVT, deep vein thrombosis; PE, pulmonary embolism; SCC, squamous-cell carcinoma; SCLC, small cell lung cancer; IVCT, intravenous chemotherapy; PD1, programmeddeath-1; TKI, tyrosine kinase inhibitor; RT, radiotherapy; HREZ, isonicotinic acid hydrazide, rifampicin, ethambutol, pyrazinamide; RBC, red blood cell count; WBC, white blood cell count; PLT, blood platelet count; PT, prothrombin time.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us